Southeast Asia Leg Of Sanofi’s Phase III Dengue Vaccine Trial Meets Primary Endpoint
This article was originally published in PharmAsia News
Sanofi Pasteur says that a vaccine candidate for dengue has met its primary endpoint in Phase III trials in Southeast Asia, capping a 20-year effort that has cost more than $1 billion. The focus now is on a second leg in Latin America with a vaccine possibly ready for the market late next year if all goes according to plan.
You may also be interested in...
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.
Asia now shoulders 63% of the world’s type 2 diabetes burden, with around 202 million cases in total and a younger onset age than the Western population. Most of these cases are in China and India, while the national prevalence of type 2 diabetes has also increased two-fold or more in many Asian countries, according to data gathered for the 10th International Diabetes Federation-Western Pacific Region held jointly with the 6th Asian Association for the Study of Diabetes in Singapore in late November.